Objectives Two promising epigenetic therapeutic targets have emerged for the treatment of
hematologic malignancies, BET and CBP/EP300 proteins. Several studies have shown that …

REDX05358 has been identified as a novel, highly selective and potent next generation pan
RAF inhibitor with improved therapeutic potential and predicted safety profile. Aberrant …

Relapse of disease and subsequent resistance to established therapies remain as major
challenges in the treatment of multiple myeloma (MM). New therapeutic options are needed …

Resistance to the RAF inhibitor vemurafenib arises commonly in melanomas driven by the
activated BRAF oncogene. Here, we report antitumor properties of RAF709, a novel ATP …

2507 Background: LY3009120, a pan-Raf and dimer inhibitor, demonstrates inhibition of
phospho-Mek/Erk and tumor growth inhibition in several non-clinical cancer models with …

TPS145 Background: The Ras/Raf/MEK/ERK cascade is frequently activated in human
cancers; MEK inhibition is an attractive therapeutic target for preventing tumor growth and …

The RAF family members, A-Raf, B-Raf, and C-Raf (or Raf-1), are intermediate molecules in
the mitogen-activated protein (MAP) kinase [Ras/Raf/MAP kinase/extracellular signal …

TPS9597 Background: Over 70,000 patients are diagnosed with malignant melanoma in the
USA every year with a high proportion occurring in young people. Although treatments …

The PI3K/Akt/mTOR pathway is activated in a variety of human tumors including B-cell non-
Hodgkin lymphoma (B-NHL). Targeting this pathway has been validated in solid and …

Introduction: Despite significant advances in the treatment of myeloma, patients invariably
become resistant to therapy. Therefore, novel treatment strategies are needed to overcome …